Status:
WITHDRAWN
N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome
Lead Sponsor:
Prisma Health-Midlands
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
We would study whether there is any measurable benefit of the administration of nebulized n-acetyl-cysteine to acute respiratory distress syndrome patients starting within 48 hours of intubation and m...
Detailed Description
Objectives / Research Aims The overall objectives of this study are to demonstrate whether a protocol for the early use of inhaled N-acetylcysteine improves mortality, ventilator days, ICU days, hospi...
Eligibility Criteria
Inclusion
- Inclusion criteria includes adult patients admitted to the medical intensive care unit or coronary care unit, being mechanically ventilated with a positive end expiratory pressure greater than 5 cm H2O, with noncardiogenic pulmonary edema on chest x-ray within 48 hours of being noted to have a P/F ratio \< 150.
Exclusion
- Exclusion criteria includes patients \< 18 years of age, patients for whom no aggressive measures are desired, patients who are already receiving "rescue methods" (prone positioning, advanced ventilator modes, paralytics), trauma patients, vulnerable patient groups (pregnant, prisoners), patients who have undergone a surgical operation during their time on the ventilator, patients with end stage liver disease, patients on chronic ventilators, and asthmatics.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03346681
Start Date
February 1 2018
End Date
January 30 2021
Last Update
October 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Palmetto Health Richland
Columbia, South Carolina, United States, 29203